<code id='400B66F27B'></code><style id='400B66F27B'></style>
    • <acronym id='400B66F27B'></acronym>
      <center id='400B66F27B'><center id='400B66F27B'><tfoot id='400B66F27B'></tfoot></center><abbr id='400B66F27B'><dir id='400B66F27B'><tfoot id='400B66F27B'></tfoot><noframes id='400B66F27B'>

    • <optgroup id='400B66F27B'><strike id='400B66F27B'><sup id='400B66F27B'></sup></strike><code id='400B66F27B'></code></optgroup>
        1. <b id='400B66F27B'><label id='400B66F27B'><select id='400B66F27B'><dt id='400B66F27B'><span id='400B66F27B'></span></dt></select></label></b><u id='400B66F27B'></u>
          <i id='400B66F27B'><strike id='400B66F27B'><tt id='400B66F27B'><pre id='400B66F27B'></pre></tt></strike></i>

          entertainment

          entertainment

          author:Wikipedia    Page View:233
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          Supreme Court to hear if Covid misinformation is protected speech
          Supreme Court to hear if Covid misinformation is protected speech

          MANDELNGAN/AFPviaGettyImagesWASHINGTON—Associalmediasiteswerefloodedwithmisleadingpostsaboutvaccines

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Can U.S. cancer drug shortages be fixed?

          AdobeRoughlytwomillionAmericansareexpectedtoreceiveacancerdiagnosisthisyear.Somemembersofthisalready